search
Back to results

Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia

Primary Purpose

Tachycardia, Supraventricular, Paroxysmal Supraventricular Tachycardia

Status
Recruiting
Phase
Phase 3
Locations
China
Study Type
Interventional
Intervention
Etripamil NS 70 mg
Placebo
Sponsored by
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Tachycardia, Supraventricular focused on measuring Etripamil, Paroxysmal supraventricular tachycardia, Cardiac monitoring, Calcium channel blocker, Conversion rate, Chinese patient

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Patients who meet all of the following criteria will be eligible to participate in the study:

  1. Male or female patients at least 18 years of age;
  2. Electrographically documented history of PSVT (e.g., diagnosis based on ECG , Holter monitoring, etc.). If patient had a prior ablation for PSVT, patient must have documented ECG evidence of PSVT post-ablation;
  3. History of sustained episodes of PSVT (i.e., typically lasting 20 minutes or longer);
  4. Females of childbearing potential who are sexually active with a male partner who is not surgically sterile (i.e., vasectomy) must agree to use an approved highly effective form of contraception from the time of signed informed consent until 30 days after the last administration of study drug.;

    The following categories define females who are NOT considered to be of childbearing potential:

    • Premenopausal females with 1 of the following:

      1. Documented hysterectomy;
      2. Documented bilateral salpingectomy or tubal ligation; or
      3. Documented bilateral oophorectomy; or
    • Postmenopausal females, defined as having amenorrhea for at least 12 months without an alternative medical cause; and
  5. Signed written informed consent.

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded from participation in the study:

  1. Systolic blood pressure (SBP) <90 mmHg after a 5-minute rest in sitting position at the Screening Visit or before the test dose. In patients treated with a chronic prophylactic drug for PSVT (e.g., beta blockers, verapamil, and diltiazem), the drug may be stopped for at least the equivalent of 5 half-lives, patients may be rescreened once, and chronic use of the drug cannot be restarted after randomization;
  2. History of severe symptoms of hypotension, especially syncope, during episodes of PSVT;
  3. History of atrial arrhythmia that does not involve the atrioventricular (AV) node as part of the tachycardia circuit (e.g., atrial fibrillation, atrial flutter, intra-atrial tachycardia);
  4. History of allergic reaction to verapamil;
  5. Current therapy with digoxin or any Class I or III antiarrhythmic drug, except if these drugs are stopped at least the equivalent of 5 half-lives before the Test Dose Randomization Visit;
  6. Current chronic therapy with oral amiodarone, or have taken oral amiodarone within 30 days prior to the Test Dose Randomization Visit;
  7. Evidence of ventricular pre-excitation (e.g., delta waves, short PR interval <100 msec, Wolff Parkinson White syndrome) on the ECG performed at the Screening Visit or before the test dose administration;
  8. Evidence of a second- or third-degree AV block on the ECG performed at the Screening Visit or before the test dose administration;
  9. History or evidence of severe ventricular arrhythmia (e.g., torsades de pointes, ventricular fibrillation, or ventricular tachycardia);
  10. Current congestive heart failure defined by the New York Heart Association Class II to IV;
  11. History of Acute Coronary Syndrome or stroke within 6 months of screening;
  12. Evidence of hepatic dysfunction ;
  13. Evidence of End-Stage Renal Disease;
  14. Females who are pregnant or lactating;
  15. Evidence or history of any significant physical or psychiatric condition including drug abuse, which, in the opinion of the Investigator, could jeopardize the safety of patients or affect their participation in the study. Additionally, the Investigator has the ability to exclude a patient if for any reason the Investigator judges the patient is not a good candidate for the study (e.g., illiteracy or poor understanding) or will not be able to follow study procedures;
  16. Participation in any investigational drug or device study or the use of any investigational drug or device within 30 days or five terminal phase half-lives of the drug whichever is longer, prior to the Screening Visit; or
  17. Previously enrolled in a clinical trial for Etripamil and received study drug during a perceived episode of PSVT;
  18. An immediate family member of the participating investigator, sub-investigator, study coordinator, or employee of the participating investigator.

Before randomization in this study, all patients will receive a test dose of an etripamil NS dosing regimen.

Sites / Locations

  • Baotou Central HospitalRecruiting
  • The First Affiliated Hospital of Baotou Medical CollegeRecruiting
  • Beijing Anzhen Hospital; Capital Medical UniversityRecruiting
  • Beijing Hospital
  • Beijing Tongren Hospital, Capital Medical University
  • Chui Yang Liu Hospital Affiliated to Tsinghua UniversityRecruiting
  • Peking Union Medical College Hospital
  • The Central Hospital of China Aerospace Corporation
  • The First Affiliated Hospital of Bengbu Medical College
  • The First Hospital of Jilin UniversityRecruiting
  • The Third Xiangya Hospital of Central South UniversityRecruiting
  • Xiangya Hospital, Central South UniversityRecruiting
  • Changzhou No.2 People's HospitalRecruiting
  • The First Affiliated Hospital of Chengdu Medical CollegeRecruiting
  • Affiliated Zhongshan Hospital of Dalian UniversityRecruiting
  • People's Hospital of Deyang CityRecruiting
  • The First Affiliated Hospital of Fujian Medical UniversityRecruiting
  • Nanfang Hospital of Southern Medical UniversityRecruiting
  • Guizhou Provincial People's HospitalRecruiting
  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
  • The First People's Hospital of Hangzhou Linping DistrictRecruiting
  • Zhejiang Provincial People's Hospital
  • Huai'an First People's HospitalRecruiting
  • Huainan First People's HospitalRecruiting
  • Huizhou Municipal Central HospitalRecruiting
  • Jinan Central HospitalRecruiting
  • Shandong Province Qianfoshan Hospital
  • The First Affiliated Hospital of Jinzhou Medical UniversityRecruiting
  • Lanzhou University Second HospitalRecruiting
  • Lishui Municipal Central Hospital
  • The First Affiliated Hospital of Henan Science and Technology UniversityRecruiting
  • Mianyang Central HospitalRecruiting
  • The Nanchang Third HospitalRecruiting
  • The Second Affiliated Hospital of Nanchang UniversityRecruiting
  • Jiangsu Province HospitalRecruiting
  • Nanjing Drum Tower Hospital
  • Guangxi Zhuang Autonomous Region People's Hospital
  • The second affiliated Hospital of Guangxi Medical UniversityRecruiting
  • Nanyang Second General HospitalRecruiting
  • Ningbo First HospitalRecruiting
  • Ruijin Hospital of Shanghai Jiaotong University School of MedicineRecruiting
  • Shanghai Pudong New Area People's HospitalRecruiting
  • Shanghai Tongren HospitalRecruiting
  • Shangrao People's Hospital
  • Shanxi Cardiovascular HospitalRecruiting
  • Jiangsu Taizhou People's Hospital
  • Binhai Hospital (Tianjin Fifth Central Hospital)Recruiting
  • Tianjin Medical University General Hospital
  • CR and WISCO General HospitalRecruiting
  • Union Hospital Tongji Medical College Huazhong University of Science and TechnologyRecruiting
  • Xingtai Third HospitalRecruiting
  • The Fourth Affiliated Hospital Zhejiang University School of MedicineRecruiting
  • ZiBo Central HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Etripamil NS 70 mg with Optional Second Dose

Placebo with Optional Second Dose

Arm Description

Dosing regimen that permits a second dose of Etripamil NS 70 mg

Dosing regimen that permits a second dose of placebo

Outcomes

Primary Outcome Measures

Time to an adjudicated termination of a positively adjudicated episode of PSVT and conversion to sinus rhythm (SR) for at least 30 seconds within 30 minutes of start of study drug dosing
The primary efficacy endpoint is defined as an adjudicated termination of a positively adjudicated episode of PSVT (AV nodal reentrant tachycardia or AV reentrant tachycardia determination if possible) and conversion to sinus rhythm (SR) for at least 30 seconds within 30 minutes of start of study drug dosing.

Secondary Outcome Measures

Time to conversion at time points of 5, 10, 15, 45, and 60 minutes
Time to conversion in patients with the option of repeat administration
The percentage of patients requiring additional medical intervention in emergency department to terminate an episode of PSVT
Number of participants with relief of specific symptoms (i.e., heart palpitations, rapid pulse feeling, chest pain, anxiety, shortness of breath, dizziness, and fainting)
Rating of Treatment Satisfaction Questionnaire for Medication (TSQM).
Treatment satisfaction will be analyzed by comparing the Treatment Satisfaction Questionnaire for Medication 9(TSQM-9) score for satisfaction in the 2 treatment groups. The TSQM-9 is composed of 9 questions with responses on a scale of 1 (extremely dissatisfied) to 7 (extremely satisfied). A higher score indicated greater satisfaction with medication.
The percentage of adverse event
Number of participants with arrhythmias and conduction disorders detected on surface electrocardiogram(ECG) or cardiac monitoring system (CMS) recordings.

Full Information

First Posted
June 5, 2022
Last Updated
September 18, 2023
Sponsor
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.
Collaborators
Milestone Pharmaceuticals Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05410860
Brief Title
Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia
Official Title
Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia in Chinese Patients
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 30, 2022 (Actual)
Primary Completion Date
June 2024 (Anticipated)
Study Completion Date
January 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.
Collaborators
Milestone Pharmaceuticals Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes

5. Study Description

Brief Summary
To determine whether etripamil nasal spray (NS) self-administered by Chinese patients is superior to placebo at terminating episodes of PSVT in an at-home setting; To evaluate the efficacy of etripamil NS self-administered by Chinese patients compared with placebo on a range of clinical markers. To evaluate the safety of etripamil NS self-administered by Chinese patients compared with placebo
Detailed Description
The study is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etripamil NS self-administered by patients who experience an episode of PSVT in an at-home setting. This is an event-driven study. Enrollment into the study will continue until the adjudication of the 180th positively adjudicated PSVT episode in patients treated with double-blind study drug during the Randomized Treatment Period required for the study's pivotal analysis. After the date of the adjudication of the 180th positively adjudicated PSVT episode, all randomized patients will be unblinded at this timepoint and enter into an approximately 6 months open-label period of the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tachycardia, Supraventricular, Paroxysmal Supraventricular Tachycardia
Keywords
Etripamil, Paroxysmal supraventricular tachycardia, Cardiac monitoring, Calcium channel blocker, Conversion rate, Chinese patient

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Patients who pass the test dose of the Etripamil NS dosing regimen will be randomized in a 1:1 ratio to Etripamil NS 70mg or placebo using an Interactive Response Technology (IRT) system.
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
500 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Etripamil NS 70 mg with Optional Second Dose
Arm Type
Experimental
Arm Description
Dosing regimen that permits a second dose of Etripamil NS 70 mg
Arm Title
Placebo with Optional Second Dose
Arm Type
Experimental
Arm Description
Dosing regimen that permits a second dose of placebo
Intervention Type
Drug
Intervention Name(s)
Etripamil NS 70 mg
Intervention Description
Etripamil NS 70 mg will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
Primary Outcome Measure Information:
Title
Time to an adjudicated termination of a positively adjudicated episode of PSVT and conversion to sinus rhythm (SR) for at least 30 seconds within 30 minutes of start of study drug dosing
Description
The primary efficacy endpoint is defined as an adjudicated termination of a positively adjudicated episode of PSVT (AV nodal reentrant tachycardia or AV reentrant tachycardia determination if possible) and conversion to sinus rhythm (SR) for at least 30 seconds within 30 minutes of start of study drug dosing.
Time Frame
Within 30 minutes of start of study drug dosing.
Secondary Outcome Measure Information:
Title
Time to conversion at time points of 5, 10, 15, 45, and 60 minutes
Time Frame
1 hour after administration of study drug
Title
Time to conversion in patients with the option of repeat administration
Time Frame
1 hour after administration of study drug
Title
The percentage of patients requiring additional medical intervention in emergency department to terminate an episode of PSVT
Time Frame
Up to 2 years
Title
Number of participants with relief of specific symptoms (i.e., heart palpitations, rapid pulse feeling, chest pain, anxiety, shortness of breath, dizziness, and fainting)
Time Frame
1 hour after administration of study drug
Title
Rating of Treatment Satisfaction Questionnaire for Medication (TSQM).
Description
Treatment satisfaction will be analyzed by comparing the Treatment Satisfaction Questionnaire for Medication 9(TSQM-9) score for satisfaction in the 2 treatment groups. The TSQM-9 is composed of 9 questions with responses on a scale of 1 (extremely dissatisfied) to 7 (extremely satisfied). A higher score indicated greater satisfaction with medication.
Time Frame
1 hour after administration of study drug
Title
The percentage of adverse event
Time Frame
Up to 2 years
Title
Number of participants with arrhythmias and conduction disorders detected on surface electrocardiogram(ECG) or cardiac monitoring system (CMS) recordings.
Time Frame
Up to 2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients who meet all of the following criteria will be eligible to participate in the study: Male or female patients at least 18 years of age; Electrographically documented history of PSVT (e.g., diagnosis based on ECG , Holter monitoring, etc.). If patient had a prior ablation for PSVT, patient must have documented ECG evidence of PSVT post-ablation; History of sustained episodes of PSVT (i.e., typically lasting 20 minutes or longer); Females of childbearing potential who are sexually active with a male partner who is not surgically sterile (i.e., vasectomy) must agree to use an approved highly effective form of contraception from the time of signed informed consent until 30 days after the last administration of study drug.; The following categories define females who are NOT considered to be of childbearing potential: Premenopausal females with 1 of the following: Documented hysterectomy; Documented bilateral salpingectomy or tubal ligation; or Documented bilateral oophorectomy; or Postmenopausal females, defined as having amenorrhea for at least 12 months without an alternative medical cause; and Signed written informed consent. Exclusion Criteria: Patients who meet any of the following criteria will be excluded from participation in the study: Systolic blood pressure (SBP) <90 mmHg after a 5-minute rest in sitting position at the Screening Visit or before the test dose. In patients treated with a chronic prophylactic drug for PSVT (e.g., beta blockers, verapamil, and diltiazem), the drug may be stopped for at least the equivalent of 5 half-lives, patients may be rescreened once, and chronic use of the drug cannot be restarted after randomization; History of severe symptoms of hypotension, especially syncope, during episodes of PSVT; History of atrial arrhythmia that does not involve the atrioventricular (AV) node as part of the tachycardia circuit (e.g., atrial fibrillation, atrial flutter, intra-atrial tachycardia); History of allergic reaction to verapamil; Current therapy with digoxin or any Class I or III antiarrhythmic drug, except if these drugs are stopped at least the equivalent of 5 half-lives before the Test Dose Randomization Visit; Current chronic therapy with oral amiodarone, or have taken oral amiodarone within 30 days prior to the Test Dose Randomization Visit; Evidence of ventricular pre-excitation (e.g., delta waves, short PR interval <100 msec, Wolff Parkinson White syndrome) on the ECG performed at the Screening Visit or before the test dose administration; Evidence of a second- or third-degree AV block on the ECG performed at the Screening Visit or before the test dose administration; History or evidence of severe ventricular arrhythmia (e.g., torsades de pointes, ventricular fibrillation, or ventricular tachycardia); Current congestive heart failure defined by the New York Heart Association Class II to IV; History of Acute Coronary Syndrome or stroke within 6 months of screening; Evidence of hepatic dysfunction ; Evidence of End-Stage Renal Disease; Females who are pregnant or lactating; Evidence or history of any significant physical or psychiatric condition including drug abuse, which, in the opinion of the Investigator, could jeopardize the safety of patients or affect their participation in the study. Additionally, the Investigator has the ability to exclude a patient if for any reason the Investigator judges the patient is not a good candidate for the study (e.g., illiteracy or poor understanding) or will not be able to follow study procedures; Participation in any investigational drug or device study or the use of any investigational drug or device within 30 days or five terminal phase half-lives of the drug whichever is longer, prior to the Screening Visit; or Previously enrolled in a clinical trial for Etripamil and received study drug during a perceived episode of PSVT; An immediate family member of the participating investigator, sub-investigator, study coordinator, or employee of the participating investigator. Before randomization in this study, all patients will receive a test dose of an etripamil NS dosing regimen.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Qiu Deng
Phone
+86-21-80311808
Email
qiu.deng@jixingbio.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lily Liu
Organizational Affiliation
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Changsheng Ma
Organizational Affiliation
Beijing Anzhen Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Baotou Central Hospital
City
Baotou
Country
China
Individual Site Status
Recruiting
Facility Name
The First Affiliated Hospital of Baotou Medical College
City
Baotou
Country
China
Individual Site Status
Recruiting
Facility Name
Beijing Anzhen Hospital; Capital Medical University
City
Beijing
ZIP/Postal Code
100032
Country
China
Individual Site Status
Recruiting
Facility Name
Beijing Hospital
City
Beijing
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Beijing Tongren Hospital, Capital Medical University
City
Beijing
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Chui Yang Liu Hospital Affiliated to Tsinghua University
City
Beijing
Country
China
Individual Site Status
Recruiting
Facility Name
Peking Union Medical College Hospital
City
Beijing
Country
China
Individual Site Status
Not yet recruiting
Facility Name
The Central Hospital of China Aerospace Corporation
City
Beijing
Country
China
Individual Site Status
Not yet recruiting
Facility Name
The First Affiliated Hospital of Bengbu Medical College
City
Bengbu
Country
China
Individual Site Status
Not yet recruiting
Facility Name
The First Hospital of Jilin University
City
Ch'ang-ch'un
Country
China
Individual Site Status
Recruiting
Facility Name
The Third Xiangya Hospital of Central South University
City
Changsha
Country
China
Individual Site Status
Recruiting
Facility Name
Xiangya Hospital, Central South University
City
Changsha
Country
China
Individual Site Status
Recruiting
Facility Name
Changzhou No.2 People's Hospital
City
Changzhou
Country
China
Individual Site Status
Recruiting
Facility Name
The First Affiliated Hospital of Chengdu Medical College
City
Chengdu
Country
China
Individual Site Status
Recruiting
Facility Name
Affiliated Zhongshan Hospital of Dalian University
City
Dalian
Country
China
Individual Site Status
Recruiting
Facility Name
People's Hospital of Deyang City
City
Deyang
Country
China
Individual Site Status
Recruiting
Facility Name
The First Affiliated Hospital of Fujian Medical University
City
Fuzhou
Country
China
Individual Site Status
Recruiting
Facility Name
Nanfang Hospital of Southern Medical University
City
Guangzhou
Country
China
Individual Site Status
Recruiting
Facility Name
Guizhou Provincial People's Hospital
City
Guiyang
Country
China
Individual Site Status
Recruiting
Facility Name
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
City
Hangzhou
Country
China
Individual Site Status
Not yet recruiting
Facility Name
The First People's Hospital of Hangzhou Linping District
City
Hangzhou
Country
China
Individual Site Status
Recruiting
Facility Name
Zhejiang Provincial People's Hospital
City
Hangzhou
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Huai'an First People's Hospital
City
Huai'an
Country
China
Individual Site Status
Recruiting
Facility Name
Huainan First People's Hospital
City
Huainan
Country
China
Individual Site Status
Recruiting
Facility Name
Huizhou Municipal Central Hospital
City
Huizhou
Country
China
Individual Site Status
Recruiting
Facility Name
Jinan Central Hospital
City
Jinan
Country
China
Individual Site Status
Recruiting
Facility Name
Shandong Province Qianfoshan Hospital
City
Jinan
Country
China
Individual Site Status
Not yet recruiting
Facility Name
The First Affiliated Hospital of Jinzhou Medical University
City
Jinzhou
Country
China
Individual Site Status
Recruiting
Facility Name
Lanzhou University Second Hospital
City
Lanzhou
Country
China
Individual Site Status
Recruiting
Facility Name
Lishui Municipal Central Hospital
City
Lishui
Country
China
Individual Site Status
Not yet recruiting
Facility Name
The First Affiliated Hospital of Henan Science and Technology University
City
Luoyang
Country
China
Individual Site Status
Recruiting
Facility Name
Mianyang Central Hospital
City
Mianyang
Country
China
Individual Site Status
Recruiting
Facility Name
The Nanchang Third Hospital
City
Nanchang
Country
China
Individual Site Status
Recruiting
Facility Name
The Second Affiliated Hospital of Nanchang University
City
Nanchang
Country
China
Individual Site Status
Recruiting
Facility Name
Jiangsu Province Hospital
City
Nanjing
Country
China
Individual Site Status
Recruiting
Facility Name
Nanjing Drum Tower Hospital
City
Nanjing
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Guangxi Zhuang Autonomous Region People's Hospital
City
Nanning
Country
China
Individual Site Status
Not yet recruiting
Facility Name
The second affiliated Hospital of Guangxi Medical University
City
Nanning
Country
China
Individual Site Status
Recruiting
Facility Name
Nanyang Second General Hospital
City
Nanyang
Country
China
Individual Site Status
Recruiting
Facility Name
Ningbo First Hospital
City
Ningbo
Country
China
Individual Site Status
Recruiting
Facility Name
Ruijin Hospital of Shanghai Jiaotong University School of Medicine
City
Shanghai
Country
China
Individual Site Status
Recruiting
Facility Name
Shanghai Pudong New Area People's Hospital
City
Shanghai
Country
China
Individual Site Status
Recruiting
Facility Name
Shanghai Tongren Hospital
City
Shanghai
Country
China
Individual Site Status
Recruiting
Facility Name
Shangrao People's Hospital
City
Shangrao
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Shanxi Cardiovascular Hospital
City
Taiyuan
Country
China
Individual Site Status
Recruiting
Facility Name
Jiangsu Taizhou People's Hospital
City
Taizhou
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Binhai Hospital (Tianjin Fifth Central Hospital)
City
Tianjin
Country
China
Individual Site Status
Recruiting
Facility Name
Tianjin Medical University General Hospital
City
Tianjin
Country
China
Individual Site Status
Not yet recruiting
Facility Name
CR and WISCO General Hospital
City
Wuhan
Country
China
Individual Site Status
Recruiting
Facility Name
Union Hospital Tongji Medical College Huazhong University of Science and Technology
City
Wuhan
Country
China
Individual Site Status
Recruiting
Facility Name
Xingtai Third Hospital
City
Xingtai
Country
China
Individual Site Status
Recruiting
Facility Name
The Fourth Affiliated Hospital Zhejiang University School of Medicine
City
Yiwu
Country
China
Individual Site Status
Recruiting
Facility Name
ZiBo Central Hospital
City
Zibo
Country
China
Individual Site Status
Recruiting

12. IPD Sharing Statement

Learn more about this trial

Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia

We'll reach out to this number within 24 hrs